Related Experiment Video

Updated: Jul 10, 2025

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.4K

Impact of Treatment With Sacubitril/Valsartan on Erectile Dysfunction in Patients With Heart Failure With Reduced

Hasan Ali Barman1, Omer Dogan2, Selim Tanyolaç1

  • 1Department of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

The American Journal of Cardiology
|November 20, 2023
PubMed

Insights

Sacubitril/valsartan (S/V) may improve sexual function in men with heart failure with reduced ejection fraction (HFrEF). This study observed improvements in erectile function after one month of S/V treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Urology

Background:

  • Chronic heart failure with reduced ejection fraction (HFrEF) significantly impacts patients' quality of life.
  • Erectile dysfunction (ED) is a common comorbidity in men with HFrEF.
  • Sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, is established for HFrEF management.

Purpose of the Study:

  • To evaluate the efficacy of Sacubitril/valsartan (S/V) in treating erectile dysfunction (ED) in male patients with HFrEF.
  • To assess changes in sexual activity and ED severity using the International Index of Erectile Function (IIEF) questionnaire.

Main Methods:

  • A prospective, open-label study involving 59 male patients diagnosed with HFrEF and ED.
  • Patients received S/V treatment for one month.
  • IIEF scores and clinical parameters were assessed at baseline and after one month.

Main Results:

  • A statistically significant increase in IIEF scores was observed post-treatment, indicating reduced ED severity.
  • Improvements in sexual activities were noted at the one-month follow-up.
  • The increase in IIEF score, while statistically significant, did not reach clinical significance.

Conclusions:

  • Sacubitril/valsartan (S/V) treatment may offer benefits for sexual function in men with HFrEF.
  • Further research is warranted to confirm the clinical significance of these findings.
  • S/V demonstrates potential as a therapeutic option addressing both cardiovascular and sexual health in HFrEF patients.

Keywords:
International Index of Erectile Functionerectile dysfunctionheart failuresacubitril/valsartansexual activities

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
398
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748